

urements should be included in the physical examination of all children 3 years old and older as part of their continuing health care. These measurements should be plotted on grids. In a child in whom levels exceed the 95th percentile on four occasions, evaluations should be done taking into account the parents' history (hypertension or its complications), the health and blood pressure levels of siblings, the patient's history and findings on physical examination of the patient. Guidelines for pharmacotherapy in stepped graduations are provided.

Finally, the *Plan for Hypertension Control for the State of California*, adopted in 1976, includes a segment dealing with children and adolescents. Further information can be obtained from Dr. Harold Mozar, Chief, Chronic Disease Control Section, State of California Department of Health.

ELLIN LIEBERMAN, MD

REFERENCES

- Report of the Task Force on Blood Pressure Control in Children—The National Heart, Lung, and Blood Institute, National Institutes of Health. *Pediatrics* 59:797-820, May 1977
Lieberman E: Childhood hypertension: Evaluation and management. *Cardiovasc Med* 1:120-128, Oct 1976

Hypothyroid Screening of Newborns

CONGENITAL HYPOTHYROIDISM probably is the most frequently occurring, preventable, congenital cause of mental retardation. Its incidence, about one in 5,000 births, is about twice that of phenylketonuria—which already is subject to mandatory newborn screening. Screening programs in North America have screened about 700,000 newborns and detected permanent congenital hypothyroidism in 166 of them; thyroid dysgenesis was found in 85 percent of the 166, inborn defects in thyroid hormonogenesis in 10 percent and hypothalamic-pituitary hypothyroidism in 5 percent. In only seven of the 166 infants was the condition suspected on clinical grounds before six weeks of age. Most of the screening programs now are testing filter paper blood spots (as used for phenylketonuria screening) for thyroxine content by radioimmunoassay and following this with a thyrotropin content radioimmunoassay on samples with the lowest 3 percent of thyroxine values. Infants with a low blood thyroxine level and a high thyrotropin level are recalled immediately for serum testing and treatment.

Infants with the lowest 1 percent of thyroxine values and low thyrotropin levels are retested at six weeks or the physician of record is notified of the low thyroxine and thyrotropin values—which may indicate prematurity, low serum thyroxine binding globulin level or hypothalamic-pituitary hypothyroidism.

Treatment of involved infants now is begun within four weeks of birth. Evaluation and preliminary IQ testing of treated newborns (after 12 months of treatment) suggests normal development. The cost of the program is \$1 to \$2 per infant screened, or \$5,000 to \$10,000 per infant in whom congenital hypothyroidism is detected. Without early diagnosis and treatment, special education is required in about 70 percent of hypothyroid infants at an estimated cost of \$30,000 per infant, and prolonged custodial care is required in 20 percent.

Newborn screening programs for congenital hypothyroidism, therefore, are effective in detection of the disorder and facilitation of early treatment, and are cost effective. Preliminary information suggests that early treatment prevents mental retardation and minimizes the impact of congenital hypothyroidism on public budgets for care and rehabilitation of the mentally handicapped.

DELBERT A. FISHER, MD

REFERENCES

- Klein AH, Foley TP Jr, Larsen PR, et al: Neonatal thyroid function in congenital hypothyroidism. *J Pediatr* 89:545-549, Oct 1976
Dussault JH, Letarte J, Guyda H, et al: Thyroid function in neonatal hypothyroidism. *J Pediatr* 89:541-544, Oct 1976

The Lung Profile: Fetal Lung Maturity

FINDINGS FROM recent studies have shown that the maturity of the lungs in a fetus can be determined using various measurements of phospholipid indicators in amniotic fluid. These phospholipids originate from surfactant produced in fetal lungs and are secreted into amniotic fluid during gestation. They include lecithin and sphingomyelin (as the L/S ratio), the percentage of disaturated lecithin (which increases during gestation to 50 percent at maturation and as high as 70 percent at term), and percentages of two acidic phospholipids, phosphatidyl inositol and phosphatidyl glycerol. These latter two phospholipids

are essential in stabilizing lecithin in surfactant. Before this new concept evolved, it had been thought that lecithin was *the* surfactant instead of *a* surfactant—as our information now shows it to be.

These measurements of phospholipids are called the lung profile. They are combined on a graph interpreted according both to weeks of gestation and to whether the lung is immature, premature, transitional, borderline mature, mature or post-term. The lung profile has been especially valuable in the management of problem pregnancies. Use of the lung profile also has made it possible to virtually eliminate intermediate, low L/S ratios where subsequent babies do not have respiratory distress syndrome (RDS), giving a clear picture of the state of lung development. Of special importance is the finding that in infants born to mothers with gestational diabetes (diabetes A) there may be a delay in maturation of the phosphatidyl glycerol. Consequently, awaiting the appearance of phosphatidyl glycerol is a way of assuring that infants born to mothers with diabetes will not have RDS.

LOUIS GLUCK, MD

REFERENCES

- Gluck L, Kulovich MV, Hallman M: The fetal lung profile: Beyond the L/S ratio. *Abstract. Pediatr Res* 11:571, Apr 1977
- Hallman M, Kulovich M, Kirkpatrick E, et al: Phosphatidylinositol and phosphatidylglycerol in amniotic fluid: Indices of lung maturity. *Am J Obstet Gynecol* 125:613-617, Jul 1, 1976

Congenital Diaphragmatic Hernia

EVIDENCE IS ACCUMULATING that some babies born with a large, congenital diaphragmatic hernia who do not survive with currently accepted management may be saved by special treatment directed to increasing pulmonary blood flow. These are infants with a fairly severe diaphragmatic hernia who, after it is repaired, do well with adequate oxygenation for 6 to 24 hours and then become hypoxemic and die. In some such patients differential cyanosis was noted, indicating right-to-left shunt through the ductus due to pulmonary artery hypertension and deficient pulmonary blood flow, or persistent fetal circulation. Infusion of vasodilator substances such as chlorpromazine, tolazoline, or acetylcholine sometimes accompanied by ligation of a patent ductus apparently has helped in a small number of cases.

Additional experimental and clinical work is under way to establish the place of manipulation of pulmonary blood flow in the management of severe congenital diaphragmatic hernia.

DAVID L. COLLINS, MD

REFERENCES

- Collins DL, Pomerance JJ, Travis KW, et al: A new approach to congenital posterolateral diaphragmatic hernia. *J Pediatr Surg* 12:149-156, Apr 1977
- Rowe RD: Commentary: Abnormal pulmonary vasoconstriction in the newborn. *Pediatrics* 59:318-320, Mar 1977
- Levy RJ, Rosenthal A, Freed MD, et al: Persistent pulmonary hypertension in a newborn with congenital diaphragmatic hernia: Successful management with tolazoline. *Pediatrics* 60:740-742, Nov 1977

ADVISORY PANEL TO THE SECTION ON PEDIATRICS

BIRT HARVEY, MD, *CMA Section on Pediatrics, Chairman*
CMA Scientific Board, Palo Alto

MILTON ARNOLD, MD
CMA Section on Pediatrics
Secretary
Torrance

SYLVIA MICIK, MD
CMA Section on Pediatrics
Assistant Secretary
University of California, San Diego

EDWARD J. OTTENHEIMER, MD
CMA Scientific Board
San Diego

MARTIN GERSHMAN, MD
CMA Scientific Board
San Francisco

JOHN MACE, MD
Loma Linda University

IRVING SCHULMAN, MD
Stanford University

ELI GOLD, MD
University of California, Davis

DONALD R. SPERLING, MD
University of California, Irvine

RICHARD J. SCHAIN, MD
University of California, Los Angeles

JOHN DOWER, MD
University of California,
San Francisco

BERNARD PORTNEY, MD
University of Southern California

PAUL WEHRLE, MD
Los Angeles

MELVIN SCHWARTZ, MD
Alameda

FREDERICK A. FRYE, MD
San Diego